{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-024851","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2023-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.699838+00:00","generated_at":"2026-06-13T06:56:03.260583+00:00","sec_items":["1.01","8.01","2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Harrow acquires VEVYE and Santen ophthalmic rights; Q2 revenue guidance >$31M","bullets":["Acquired U.S./Canadian rights to VEVYE (cyclosporine 0.1%) from Novaliq; $8M upfront + low double-digit royalties.","Acquired exclusive commercial rights to Santen ophthalmic products; $8M initial payment + milestone/royalty payments.","Preliminary Q2 2023 revenue >$31M (vs $23.3M prior year); Adj EBITDA >$9.3M.","Oaktree credit facility increased to $112.5M; $12.5M draw to fund Santen acquisition.","Proposed underwritten public offering of common stock; B. Riley Securities as book-runner."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-024851","json":"https://secwatch.observer/filing/0001493152-23-024851.json","markdown":"https://secwatch.observer/filing/0001493152-23-024851.md","text":"https://secwatch.observer/filing/0001493152-23-024851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315223024851/0001493152-23-024851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315223024851/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T06:56:03.260583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b1835af9358f0e9072cf744eccc04678df85317f","claim":"HARROW, INC. reported second quarter 2023 results: revenue in excess of $31.0 million.","evidence_excerpt":"Management expects the Company to record over $31,000,000 of total revenues and over $9,300,000 of Adjusted EBITDA (a non-GAAP measure) for the three-month period ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1360214/000149315223024851/0001493152-23-024851-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Revenue","value":"in excess of $31.0 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"b1835af9358f0e9072cf744eccc04678df85317f","claim":"HARROW, INC. reported second quarter 2023 results: revenue in excess of $31.0 million.","evidence_excerpt":"Second quarter 2023 revenues in excess of $31.0 million compared with prior-year second quarter revenues of $23.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1360214/000149315223024851/0001493152-23-024851-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Revenue","value":"in excess of $31.0 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"b036e520d7cc0f2b323039a6716ef54de1342bca","claim":"HARROW, INC. amended Oaktree Amendment with Oaktree Fund Administration, LLC valued at from $100,000,000 to $112,500,000 (effective 2023-07-18).","evidence_excerpt":"On July 18, 2023, Harrow Health, Inc. (the \"Company\") entered into the First Amendment to Credit Agreement and Guaranty and Consent (the \"Oaktree Amendment\") to the Credit Agreement and Guaranty (the \"Oaktree Loan\") originally entered into on March 27, 2023, with the lenders from time to time party thereto and Oaktree Fund Administration, LLC, as administrative agent for the lenders (together, \"Oaktree\"). Under the Oaktree Amendment, the overall credit facility size was increased from $100,000,000 to $112,500,000, and the Company made other changes related to the Santen Products Acquisition","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1360214/000149315223024851/0001493152-23-024851-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oaktree Fund Administration, LLC"},{"label":"Value","value":"from $100,000,000 to $112,500,000"},{"label":"Effective","value":"2023-07-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}